Advisors Asset Management Inc. Sells 783 Shares of Amedisys, Inc. (NASDAQ:AMED)

Advisors Asset Management Inc. reduced its position in Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 31.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,707 shares of the health services provider’s stock after selling 783 shares during the quarter. Advisors Asset Management Inc.’s holdings in Amedisys were worth $179,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMED. Spears Abacus Advisors LLC raised its holdings in shares of Amedisys by 58.5% in the second quarter. Spears Abacus Advisors LLC now owns 33,677 shares of the health services provider’s stock valued at $3,540,000 after buying an additional 12,429 shares during the last quarter. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income grew its position in shares of Amedisys by 4,455.7% during the 2nd quarter. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income now owns 53,530 shares of the health services provider’s stock worth $5,627,000 after buying an additional 52,355 shares during the period. Texas Permanent School Fund grew its position in shares of Amedisys by 1.8% during the 2nd quarter. Texas Permanent School Fund now owns 23,525 shares of the health services provider’s stock worth $2,473,000 after buying an additional 412 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Amedisys during the 2nd quarter valued at about $770,000. Finally, State Board of Administration of Florida Retirement System lifted its holdings in shares of Amedisys by 1.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 38,083 shares of the health services provider’s stock valued at $4,003,000 after purchasing an additional 693 shares in the last quarter. 93.36% of the stock is owned by institutional investors.

Amedisys Trading Up 0.7 %

Shares of Amedisys stock opened at $86.55 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.06 and a current ratio of 1.06. Amedisys, Inc. has a 52 week low of $83.00 and a 52 week high of $179.91. The stock has a 50 day moving average price of $97.98 and a two-hundred day moving average price of $111.66. The stock has a market capitalization of $2.81 billion, a PE ratio of 23.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.99.

Amedisys (NASDAQ:AMEDGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The health services provider reported $1.15 EPS for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.07). Amedisys had a net margin of 5.45% and a return on equity of 16.00%. The firm had revenue of $557.99 million during the quarter, compared to analyst estimates of $579.30 million. During the same period last year, the business posted $1.53 EPS. The company’s revenue was up .8% on a year-over-year basis. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Cowen cut their target price on Amedisys to $103.00 in a research note on Friday, November 4th. Benchmark decreased their target price on Amedisys from $165.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, October 3rd. Raymond James lowered Amedisys from an “outperform” rating to a “market perform” rating in a report on Thursday, October 27th. Stephens decreased their price objective on Amedisys from $122.00 to $106.00 and set an “equal weight” rating on the stock in a report on Friday, November 11th. Finally, SVB Leerink reduced their target price on Amedisys from $116.00 to $96.00 and set a “market perform” rating on the stock in a report on Tuesday, November 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $136.13.

Amedisys Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.

Featured Articles

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.